P1049: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent Kit D816V Inhibitor, in Adults With Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights

DeAngelo, D. J., Pullarkat, V., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Pilla, A., Massaro, M., Exter, B., Jolin, H. A., Mikhak, Z., & Tashi, T. (2022). P1049: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent Kit D816V Inhibitor, in Adults With Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights. HemaSphere, 6, 939–940. https://doi.org/10.1097/01.hs9.0000847064.38588.9b

Authors:
Daniel J. DeAngelo
Vinod Pullarkat
Miguel Piris‐Villaespesa
Tracy I. George
Janaki Patel
Celalettin Üstün
P. Bose
Mark Heaney
A. Pilla
M. Massaro
B. Exter
H. A. Jolin
Z. Mikhak
Tsewang Tashi
Affiliated Authors:
Mark Heaney
Publication Type:
Article
Unique ID:
10.1097/01.hs9.0000847064.38588.9b
Journal:
Publication Date:
Data Source:
OpenAlex

Record Created: